Methodology

All entries for: Investment

December 23, 2025

GEn1E Lifesciences

Investment

GEn1E Lifesciences raised $5.52 million to accelerate first in class precision therapies for inflammatory & rare diseases.

Disease Area: Rare Diseases
Source
Source
December 18, 2025

Atavistik Bio

Investment

Atavistik Bio raised $120 million to to advance its selective oral AKT1 inhibitor for hereditary hemorrhagic telangiectasia (HHT), a severe rare bleeding disorder.

Disease Area: Rare Diseases
Source
Source
December 17, 2025

Addition Therapeutics

Investment

Addition Therapeutics raised $106.5 million to advance its all-RNA PRINT™ platform and expand genomic medicine approaches for both chronic and rare diseases.

Disease Area: Rare Diseases
Source
Source
December 16, 2025

Ambros Therapeutics

Investment

Ambros Therapeutics raised $154 million to further develop its lead investigational program for complex regional pain syndrome type 1 (CRPS-1), a rare and debilitating metabolic bone disease.

Disease Area: Rare Diseases
Source
Source
December 1, 2025

Endios Bio

Investment

Baton Rouge, LA
1-50 employees

Endios Bio raised an undisclosed amount of funding to advance its first-in-class PEG10-targeted therapeutics for amyotrophic lateral sclerosis (ALS) and related neurodevelopmental disorders.

Disease Area: Rare Diseases
Source
Source
December 1, 2025

Mantle Therapeutics

Investment

Mantle Bio raised an undisclosed amount of funding to develop therapies for rare, fatal diseases lacking curative options.

Disease Area: Rare Diseases
Source
Source
December 1, 2025

Protego Biopharma

Investment

Protego Biopharma raised $130 million to advance PROT-001 into a pivotal clinical trial for AL amyloidosis, a rare and often fatal protein misfolding disorder that leads to progressive organ damage, particularly in the heart.

Disease Area: Rare Diseases
Source
Source
November 24, 2025

Neela Therapeutics

Investment

Neela Therapeutics raised $12.01 million to develop a pediatric central nervous system therapy designed to address rare neuro-genetic diseases.

Disease Area: Rare Diseases
Source
Source
November 21, 2025

Phoenics

Investment

Phoenics raised $13.81 million to develop therapies for patients living with rare diseases.

Disease Area: Rare Diseases
Source
Source
November 17, 2025

VasoRx

Investment

VasoRx raised $28.89 million to advance its RNA therapy platform for the treatment of pulmonary hypertension, a rare cardiovascular disease.

Disease Area: Rare Diseases
Source
Scroll to Top